Effect and safety of ticagrelor combined with aspirin in treating cerebral infarction at acute stage

Lin Bin; Sheng Di

doi:10.3760/cma.j.issn.1673-4777.2016.04.015

Abstract：Objective To observe the effect and safety of ticagrelor combined with aspirin in treating cerebral infarction at acute stage.Methods Totally 81 patients with cerebral infarction at acute stage from January 2014 and February 2015 were randomly divided into control group (40 cases) and combination group (41 cases).Both group were given therapy of controlling blood pressure,blood glucose and blood lipid and neurotrophy treatment;in addition,aspirin enteric tablets (100 mg/d,1 time/d) was orally administrated in control group,aspirin enteric tablets plus ticagrelor (90 mg/time,2 times/d,180 mg at the first time) were orally administrated in combination group for 14 d.The high-sensitivity C-reactive protein (hs-CRP),platelet aggregation rate,national institute of health stroke scale (NIHSS) scores before and after treatment were measured,the effect and adverse reaction were observed.Results The hs-CRP,platelet aggregation rate were not significantly different between groups before treatment (P ＞0.05).After 7 d of treatment,the hs-CRP was significantly increase,the platelet aggregation rate was significantly reduced compared with those before treatment in control group [(12 ± 3) mg/L vs (7 ±3) mg/L,(31 ± 11)％ vs (57 ± 12)％] and combination group [(10 ±3) mg/L vs (6 ±3) mg/L,(14 ± 12)％ vs (57 ± 11)％],moreover,the hs-CRP and platelet aggregation rate in combination group were significantly lower than those in control group after treatment (P ＜ 0.05).The effective rate in combination group was significantly higher than that in control group [95.1％ (39/41) vs 87.5％ (35/40)] (P ＜ 0.05).No adverse events occurred in both groups.Conclusion Combination of ticagrelor and aspirin is better than single aspirin in treatment of cerebral infarction at acute stage,with high safety.